English

CONSTELLATION PHARMACEUTICALS INC

EDGAR

CNST Quarterly report (10-Q) · filed 2021-05-10

14 filing records in this dataset, filed from 2018-06-22 to 2021-05-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2018 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-13.5 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -48823000 USD Source
Operating Cash Flow: -35303000 USD Source

Free cash flow

-13.9 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -48823000 USD Source
Operating Cash Flow: -35303000 USD Source
Capital Expenditure: 476000 USD Source
Capital Expenditure: 124000 USD Source

Cash and cash equivalents: 114 million USD 2021-03-31 Source
Exact value

113983000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 47.9 million shares 2021-03-31 Source
Exact value

47913147 shares

Reported share-count change

14.56% · 6.09 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

41822064 shares · 2020-03-31· Source
47913147 shares · 2021-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Revenue: 0 USD · 2018-01-01 – 2018-03-31 Source
Revenue: 0 USD · 2018-04-01 – 2018-06-30 Source
Revenue: 0 USD · 2018-07-01 – 2018-09-30 Source
Revenue: 0 USD · 2018-10-01 – 2018-12-31 Source

Net income

-141 million USD

2020-04-01 – 2021-03-31

Exact inputs and evidence

Net income: -29753000 USD · 2020-04-01 – 2020-06-30 Source
Net income: -33776000 USD · 2020-07-01 – 2020-09-30 Source
Net income: -37384000 USD · 2020-10-01 – 2020-12-31 Source
Net income: -40072000 USD · 2021-01-01 – 2021-03-31 Source

Operating cash flow

-125 million USD

2020-04-01 – 2021-03-31

Exact inputs and evidence

Operating cash flow: -47063000 USD · 2020-01-01 – 2020-06-30 Source
Operating cash flow: -26030000 USD · 2020-01-01 – 2020-03-31 Source
Operating cash flow: -77873000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -47063000 USD · 2020-01-01 – 2020-06-30 Source
Operating cash flow: -111424000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: -77873000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -39738000 USD · 2021-01-01 – 2021-03-31 Source

Capital expenditure

1.4 million USD

2020-04-01 – 2021-03-31

Exact inputs and evidence

Capital expenditure: 161000 USD · 2020-01-01 – 2020-06-30 Source
Capital expenditure: 38000 USD · 2020-01-01 – 2020-03-31 Source
Capital expenditure: 807000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 161000 USD · 2020-01-01 – 2020-06-30 Source
Capital expenditure: 946000 USD · 2020-01-01 – 2020-12-31 Source
Capital expenditure: 807000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 490000 USD · 2021-01-01 – 2021-03-31 Source

Free cash flow

-127 million USD

2020-04-01 – 2021-03-31

Exact inputs and evidence

Operating cash flow: -47063000 USD · 2020-01-01 – 2020-06-30 Source
Operating cash flow: -26030000 USD · 2020-01-01 – 2020-03-31 Source
Operating cash flow: -77873000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -47063000 USD · 2020-01-01 – 2020-06-30 Source
Operating cash flow: -111424000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: -77873000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -39738000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 161000 USD · 2020-01-01 – 2020-06-30 Source
Capital expenditure: 38000 USD · 2020-01-01 – 2020-03-31 Source
Capital expenditure: 807000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 161000 USD · 2020-01-01 – 2020-06-30 Source
Capital expenditure: 946000 USD · 2020-01-01 – 2020-12-31 Source
Capital expenditure: 807000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 490000 USD · 2021-01-01 – 2021-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-05-10.

Financial data available through: 2020-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2018-12-31
Operating income: 5 of 11 periods available· newest 2020-12-31
Net income: 5 of 11 periods available· newest 2020-12-31
Operating cash flow: 5 of 11 periods available· newest 2020-12-31
Capital expenditure: 5 of 11 periods available· newest 2020-12-31
Total assets: 4 of 11 periods available· newest 2020-12-31
Total liabilities: 4 of 11 periods available· newest 2020-12-31
Current assets: 4 of 11 periods available· newest 2020-12-31
Current liabilities: 4 of 11 periods available· newest 2020-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2020-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2020-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 40.85 million

Prior period

−USD 85.55 million

2019-01-01 – 2019-12-31
Current period

−USD 126.4 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-126400000 − -85550000 = -40850000 USD

-85550000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-126400000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CONSTELLATION PHARMACEUTICALS INC · 2020-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Year-over-year change in Net income: -40850000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -126400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021025723/cnst-10q_20210331.htm#748520 Filing: 000156459021025723 Input fundies:NetIncome: -85550000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#3384695 Filing: 000156459021007783
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 39.18 million

Prior period

−USD 72.25 million

2019-01-01 – 2019-12-31
Current period

−USD 111.42 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-111424000 − -72248000 = -39176000 USD

-72248000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-111424000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CONSTELLATION PHARMACEUTICALS INC · 2020-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Year-over-year change in Operating cash flow: -39176000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -111424000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2327124 Filing: 000156459021007783 Input fundies:OperatingCashFlow: -72248000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2329089 Filing: 000156459021007783
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+35.3%

Prior period

USD 699,000

2019-01-01 – 2019-12-31
Current period

USD 946,000

2020-01-01 – 2020-12-31

Exact inputs and evidence

946000 − 699000 = 247000 USD

699000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
946000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CONSTELLATION PHARMACEUTICALS INC · 2020-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Year-over-year change in Capital expenditure: 247000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 946000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2343980 Filing: 000156459021007783 Input fundies:CapitalExpenditure: 699000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2345725 Filing: 000156459021007783
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2018-01-01 – 2018-12-31

Revenue USD 0
Operating costs Derived USD 61.24 million
Operating income −USD 61.24 million
Tax, interest and other Derived −USD 1.32 million
Net income −USD 59.93 million

Cash

Operating cash flow −USD 48.82 million
Capital expenditure USD 476,000
Free cash flow Derived −USD 49.3 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	33658000 Derived	-33658000	875000 Derived	-34533000	-33723000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -33658000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -34533000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -32775000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 948000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	39088000 Derived	-39088000	-3711000 Derived	-35377000	-38168000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -39088000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -35377000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -37586000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 582000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	61244000 Derived	-61244000	-1319000 Derived	-59925000	-49299000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -61244000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -59925000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -48823000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 476000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2018

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20162016-12-31	Revenue	Revenue: 0 Open source
20172017-12-31	Revenue	Revenue: 0 Open source
20182018-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -33658000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -39088000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -61244000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -34533000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -35377000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -59925000 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -32775000 Open source Capital Expenditure: 948000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -37586000 Open source Capital Expenditure: 582000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -48823000 Open source Capital Expenditure: 476000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -48.8M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-32775000	Operating Cash Flow: -32775000 Open source
20172017-12-31	Operating cash flow	-37586000	Operating Cash Flow: -37586000 Open source
20182018-12-31	Operating cash flow	-48823000	Operating Cash Flow: -48823000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -49.3M 2018

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-33723000	Operating Cash Flow: -32775000 Open source Capital Expenditure: 948000 Open source
20172017-12-31	Free cash flow	-38168000	Operating Cash Flow: -37586000 Open source Capital Expenditure: 582000 Open source
20182018-12-31	Free cash flow	-49299000	Operating Cash Flow: -48823000 Open source Capital Expenditure: 476000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

12.4% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
20172017-12-31	Liabilities / assets	61.3%	Total Liabilities: 11708000 Open source Total Assets: 19103000 Open source
20182018-12-31	Liabilities / assets	12.4%	Total Liabilities: 14780000 Open source Total Assets: 118938000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
20172017-12-31	Current assets / current liabilities	1.59×	Current Assets: 17722000 Open source Current Liabilities: 11131000 Open source
20182018-12-31	Current assets / current liabilities	8×	Current Assets: 117303000 Open source Current Liabilities: 14660000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 34.53 million Exact value Exact value: -34533000 USD 2016-01-01 – 2016-12-31: -34533000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONSTELLATION PHARMACEUTICALS INC · 2016-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Net Income: -34533000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -34533000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459019007860/cnst-20181231.xml#106628 Filing: 000156459019007860 The citation records this snapshot. The page link may show a newer release later.	−USD 32.78 million Exact value Exact value: -32775000 USD 2016-01-01 – 2016-12-31: -32775000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONSTELLATION PHARMACEUTICALS INC · 2016-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Operating Cash Flow: -32775000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32775000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459019007860/cnst-20181231.xml#131150 Filing: 000156459019007860 The citation records this snapshot. The page link may show a newer release later.	USD 948,000 Exact value Exact value: 948000 USD 2016-01-01 – 2016-12-31: 948000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONSTELLATION PHARMACEUTICALS INC · 2016-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Capital Expenditure: 948000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 948000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459019007860/cnst-20181231.xml#131780 Filing: 000156459019007860 The citation records this snapshot. The page link may show a newer release later.	−USD 33.72 million Calculation and evidence -32775000 − 948000 USD Exact free cash flow: -33723000 USD 2016-01-01 – 2016-12-31: -32775000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 948000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONSTELLATION PHARMACEUTICALS INC · 2016-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Free cash flow: -33723000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32775000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459019007860/cnst-20181231.xml#131150 Filing: 000156459019007860 Input fundies:CapitalExpenditure: 948000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459019007860/cnst-20181231.xml#131780 Filing: 000156459019007860 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 35.38 million Exact value Exact value: -35377000 USD 2017-01-01 – 2017-12-31: -35377000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONSTELLATION PHARMACEUTICALS INC · 2017-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Net Income: -35377000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35377000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459020009735/cnst-20191231.xml#111333 Filing: 000156459020009735 The citation records this snapshot. The page link may show a newer release later.	−USD 37.59 million Exact value Exact value: -37586000 USD 2017-01-01 – 2017-12-31: -37586000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONSTELLATION PHARMACEUTICALS INC · 2017-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Operating Cash Flow: -37586000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37586000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459020009735/cnst-20191231.xml#137594 Filing: 000156459020009735 The citation records this snapshot. The page link may show a newer release later.	USD 582,000 Exact value Exact value: 582000 USD 2017-01-01 – 2017-12-31: 582000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONSTELLATION PHARMACEUTICALS INC · 2017-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Capital Expenditure: 582000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 582000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459020009735/cnst-20191231.xml#138426 Filing: 000156459020009735 The citation records this snapshot. The page link may show a newer release later.	−USD 38.17 million Calculation and evidence -37586000 − 582000 USD Exact free cash flow: -38168000 USD 2017-01-01 – 2017-12-31: -37586000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 582000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONSTELLATION PHARMACEUTICALS INC · 2017-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Free cash flow: -38168000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37586000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459020009735/cnst-20191231.xml#137594 Filing: 000156459020009735 Input fundies:CapitalExpenditure: 582000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459020009735/cnst-20191231.xml#138426 Filing: 000156459020009735 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 59.93 million Exact value Exact value: -59925000 USD 2018-01-01 – 2018-12-31: -59925000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONSTELLATION PHARMACEUTICALS INC · 2018-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Net Income: -59925000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -59925000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#3386564 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	−USD 48.82 million Exact value Exact value: -48823000 USD 2018-01-01 – 2018-12-31: -48823000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONSTELLATION PHARMACEUTICALS INC · 2018-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Operating Cash Flow: -48823000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48823000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2331043 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	USD 476,000 Exact value Exact value: 476000 USD 2018-01-01 – 2018-12-31: 476000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONSTELLATION PHARMACEUTICALS INC · 2018-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Capital Expenditure: 476000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 476000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2347460 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	−USD 49.3 million Calculation and evidence -48823000 − 476000 USD Exact free cash flow: -49299000 USD 2018-01-01 – 2018-12-31: -48823000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 476000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONSTELLATION PHARMACEUTICALS INC · 2018-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Free cash flow: -49299000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48823000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2331043 Filing: 000156459021007783 Input fundies:CapitalExpenditure: 476000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2347460 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 85.55 million Exact value Exact value: -85550000 USD 2019-01-01 – 2019-12-31: -85550000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONSTELLATION PHARMACEUTICALS INC · 2019-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Net Income: -85550000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -85550000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#3384695 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	−USD 72.25 million Exact value Exact value: -72248000 USD 2019-01-01 – 2019-12-31: -72248000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONSTELLATION PHARMACEUTICALS INC · 2019-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Operating Cash Flow: -72248000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -72248000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2329089 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	USD 699,000 Exact value Exact value: 699000 USD 2019-01-01 – 2019-12-31: 699000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONSTELLATION PHARMACEUTICALS INC · 2019-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Capital Expenditure: 699000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 699000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2345725 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	−USD 72.95 million Calculation and evidence -72248000 − 699000 USD Exact free cash flow: -72947000 USD 2019-01-01 – 2019-12-31: -72248000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 699000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONSTELLATION PHARMACEUTICALS INC · 2019-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Free cash flow: -72947000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -72248000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2329089 Filing: 000156459021007783 Input fundies:CapitalExpenditure: 699000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2345725 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 126.4 million Exact value Exact value: -126400000 USD 2020-01-01 – 2020-12-31: -126400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONSTELLATION PHARMACEUTICALS INC · 2020-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Net Income: -126400000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -126400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021025723/cnst-10q_20210331.htm#748520 Filing: 000156459021025723 The citation records this snapshot. The page link may show a newer release later.	−USD 111.42 million Exact value Exact value: -111424000 USD 2020-01-01 – 2020-12-31: -111424000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONSTELLATION PHARMACEUTICALS INC · 2020-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Operating Cash Flow: -111424000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -111424000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2327124 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	USD 946,000 Exact value Exact value: 946000 USD 2020-01-01 – 2020-12-31: 946000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONSTELLATION PHARMACEUTICALS INC · 2020-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Capital Expenditure: 946000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 946000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2343980 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.	−USD 112.37 million Calculation and evidence -111424000 − 946000 USD Exact free cash flow: -112370000 USD 2020-01-01 – 2020-12-31: -111424000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 946000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONSTELLATION PHARMACEUTICALS INC · 2020-12-31 CONSTELLATION PHARMACEUTICALS INC (edgar:1434418) Free cash flow: -112370000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:18Z Snapshot: 219ad1d0650f929a2c2bf73902452d1a695eb925217d012cb7bc5dd295ebba34 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1434418?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -111424000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2327124 Filing: 000156459021007783 Input fundies:CapitalExpenditure: 946000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1434418/000156459021007783/cnst-10k_20201231.htm#2343980 Filing: 000156459021007783 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

14 filings · 822 latest values · 822 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001434418, 1434418, CNST, edgar:1434418

Also known as CONSTELLATION PHARMACEUTICALS INC

CONSTELLATION PHARMACEUTICALS INC

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2018 2018-01-01 – 2018-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation